AKBA MEXC RealStocks
Own real AKBA shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-12 11:57:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Akebia Therapeutics, Inc. (AKBA) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0.56, with a market capitalization of $150.44M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.36 to $1.89. This page covers its latest market performance, valuation, price trends and company information.
$150.44M | |
$0.56 | |
$0.56 | |
$0.56 | |
$0.57 | |
255.00 | |
8.26M | |
-- | |
$1.89 | |
$0.36 | |
-- | |
-- |
Akebia Therapeutics, Inc. (AKBA) is trading at $0.56 in pre-market trading as of 2026-11-12 09:58:00, down 2.39% ($0.01) from the previous close of $0.57
Pre-market trading shows how investors are pricing AKBA before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, Akebia Therapeutics, Inc. (AKBA) moved from $0.73 to $0.56, representing a decline of 22.84% ($0.17).
The stock traded between $0.36 and $0.75 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 10.41 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 13.0%
AKBA is currently trading at $0.56, placing it 13.0% of the way from its 52-week low of $0.36 to its 52-week high of $1.89. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 194 |
| Exchange | NASDAQ |
| Company Website |
View the latest dividend and stock split events for Akebia Therapeutics, Inc.
Dividend | |
|---|---|
| Ex-Dividend Date | -- |
| Payment Date | -- |
| Dividend Per Share | -- |
Stock Split | |
|---|---|
| Split Date | -- |
| Split Ratio | -- |
Eligible investors can buy real shares of Akebia Therapeutics, Inc. (AKBA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to AKBA, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between AKBA shares and USD.
AKBA Shares to USD
1.00 AKBA shares = 0.56 USD
Calculations are estimates based on the latest available price and are for reference only.